27819344|t|Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK -dependent p21 signaling pathway
27819344|a|SL4, a chalcone -based compound, has been shown to retard tumor invasion and angiogenesis by suppressing HIF1 activity and to induce apoptosis by promoting ROS release. Here, we report that SL4 is able to inhibit the proliferation of different types of breast cancer cell in vitro and in vivo by inducing G2/M cell cycle arrest. Our results showed that SL4 exhibited strong anti-proliferative activity in several human breast cancer cell lines, with IC50 values lower than 1.3 μM. Further studies indicated that SL4 induced G2/M arrest in these cell lines. Mechanistically, SL4 reduces the expression of cyclin A2 and cdc25C and decreases the activity of the cdc2 / cyclin B1 complex. Notably, SL4 treatment resulted in an obvious increase in p21 mRNA and protein levels through activation of MAPK signaling pathways, but not the TGF-β pathway. SP600125 and PD98059, specific inhibitors of JNK kinase and ERK kinase, significantly blocked the SL4 - induced G2/M phase arrest and upregulation of p21. Furthermore, SL4 suppressed the growth of established breast tumors in nude mice through upregulation of p21 and downregulation of cdc25C, and displayed a good safety profile. Taken together, these findings demonstrate the potential value of SL4 as a novel multi-target anti-tumor drug candidate.
27819344	0	19	Anti-tumor activity	T042	C1516031
27819344	23	26	SL4	T109	C4278992
27819344	35	54	breast cancer cells	T025	C1512505
27819344	56	65	induction	T169	C0205263
27819344	69	80	G2/M arrest	T044	C1517345
27819344	89	99	modulation	UnknownType	C0678672
27819344	107	111	MAPK	T116,T126	C0752312
27819344	123	126	p21	T116,T123	C0288472
27819344	127	144	signaling pathway	T043	C0037083
27819344	145	148	SL4	T109	C4278992
27819344	152	160	chalcone	T109	C0007935
27819344	168	176	compound	T103	C1706082
27819344	196	202	retard	T080	C0521111
27819344	203	217	tumor invasion	T033	C1269955
27819344	222	234	angiogenesis	T191	C1519670
27819344	238	249	suppressing	T169	C1260953
27819344	250	254	HIF1	T116,T123	C0215848
27819344	255	263	activity	T052	C0441655
27819344	271	277	induce	T169	C0205263
27819344	278	287	apoptosis	T043	C0162638
27819344	291	300	promoting	T052	C0033414
27819344	301	304	ROS	T123,T196	C0162772
27819344	305	312	release	T169	C1283071
27819344	323	329	report	T170	C0684224
27819344	335	338	SL4	T109	C4278992
27819344	350	357	inhibit	T052	C3463820
27819344	362	375	proliferation	T043	C0596290
27819344	379	388	different	T080	C1705242
27819344	389	394	types	T080	C0332307
27819344	398	416	breast cancer cell	T025	C1512505
27819344	417	425	in vitro	T080	C1533691
27819344	430	437	in vivo	T082	C1515655
27819344	441	449	inducing	T169	C0205263
27819344	450	472	G2/M cell cycle arrest	T044	C1517345
27819344	478	485	results	T033	C0683954
27819344	498	501	SL4	T109	C4278992
27819344	502	511	exhibited	T169	C0870432
27819344	512	518	strong	T080	C0442821
27819344	519	537	anti-proliferative	T109,T121	C0003392
27819344	538	546	activity	T052	C0441655
27819344	558	563	human	T016	C0086418
27819344	564	577	breast cancer	T191	C0678222
27819344	578	588	cell lines	T025	C0085983
27819344	595	606	IC50 values	T081	C0600495
27819344	607	612	lower	T052	C2003888
27819344	634	641	studies	T062	C2603343
27819344	642	651	indicated	T033	C1444656
27819344	657	660	SL4	T109	C4278992
27819344	661	668	induced	T169	C0205263
27819344	669	680	G2/M arrest	T044	C1517345
27819344	690	700	cell lines	T025	C0085983
27819344	702	717	Mechanistically	T022	C0598002
27819344	719	722	SL4	T109	C4278992
27819344	723	730	reduces	T080	C0392756
27819344	735	745	expression	T045	C0017262
27819344	749	758	cyclin A2	T116,T123	C0297674
27819344	763	769	cdc25C	T116,T126	C0213045
27819344	774	783	decreases	T081	C0547047
27819344	788	796	activity	T044	C1537044
27819344	804	808	cdc2	T116,T126	C0080054
27819344	811	820	cyclin B1	T116,T123	C0385333
27819344	821	828	complex	T104	C1704241
27819344	839	842	SL4	T109	C4278992
27819344	843	852	treatment	T061	C1533734
27819344	853	864	resulted in	T169	C0332294
27819344	876	884	increase	T169	C0442805
27819344	888	891	p21	T028	C0249197
27819344	892	896	mRNA	T114,T123	C0035696
27819344	901	908	protein	T116,T123	C0033684
27819344	909	915	levels	T080	C0441889
27819344	924	934	activation	T043	C2259058
27819344	938	961	MAPK signaling pathways	T043	C1518102
27819344	975	988	TGF-β pathway	T044	C1155363
27819344	990	998	SP600125	T109,T121	C0968383
27819344	1003	1010	PD98059	T109,T121	C0298346
27819344	1021	1031	inhibitors	T120	C0243077
27819344	1035	1045	JNK kinase	T116,T126	C0291988
27819344	1050	1060	ERK kinase	T116,T126	C0600388
27819344	1062	1075	significantly	T078	C0750502
27819344	1076	1083	blocked	T169	C0332206
27819344	1088	1091	SL4	T109	C4278992
27819344	1094	1101	induced	T169	C0205263
27819344	1102	1119	G2/M phase arrest	T044	C1517345
27819344	1124	1136	upregulation	T044	C0041904
27819344	1140	1143	p21	T116,T123	C0288472
27819344	1158	1161	SL4	T109	C4278992
27819344	1162	1172	suppressed	T169	C1260953
27819344	1177	1183	growth	T043	C0007595
27819344	1187	1198	established	T080	C0443211
27819344	1199	1212	breast tumors	T191	C1458155
27819344	1216	1225	nude mice	T015	C0025932
27819344	1234	1246	upregulation	T044	C0041904
27819344	1250	1253	p21	T116,T123	C0288472
27819344	1258	1272	downregulation	T044	C0013081
27819344	1276	1282	cdc25C	T116,T126	C0213045
27819344	1288	1297	displayed	T169	C0870432
27819344	1305	1311	safety	T068	C0036043
27819344	1312	1319	profile	T169	C2003903
27819344	1343	1351	findings	T033	C0243095
27819344	1352	1363	demonstrate	T080	C0443211
27819344	1368	1377	potential	T080	C3245505
27819344	1378	1383	value	T080	C1264628
27819344	1387	1390	SL4	T109	C4278992
27819344	1402	1440	multi-target anti-tumor drug candidate	T109,T121	C0003392